Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab

BACKGROUND: Cisplatin-based concurrent chemoradiotherapy is standard of care for locally advanced head and neck cancers (LAHNC). Nedaplatin, lobaplatin and nimotuzumab have shown anti-cancer effect with less gastrointestinal toxicity and nephrotoxicity. However, the profile of hematological toxiciti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qiuji, Zhu, Chunmei, Zhang, Shuyuan, Zhou, Yunfeng, Zhong, Yahua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566976/
https://www.ncbi.nlm.nih.gov/pubmed/34746003
http://dx.doi.org/10.3389/fonc.2021.762366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566976/
https://www.ncbi.nlm.nih.gov/pubmed/34746003
http://dx.doi.org/10.3389/fonc.2021.762366

Ejemplares similares